Aeon Biopharma Financials
This page shows Aeon Biopharma (AEON) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AEON’s business mechanic is financing-dependent cash burn, with losses narrowing because R&D spending fell faster than overhead.
Between FY2022 and FY2025, operating loss shrank from-$48.4M to-$12.8M , but that improvement came mostly from R&D dropping from$34.8M to$4.1M while SG&A stayed near$12.2M ; the company looks smaller, not scaled. Because free cash flow and operating cash flow were both about-$17.3M in FY2025, the cash need is coming from day-to-day operations rather than heavy reinvestment.
FY2025 ended with only
With liabilities of
Financial Health Signals
Aeon Biopharma does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Aeon Biopharma's EBITDA was -$12.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Aeon Biopharma recorded an outflow of $17.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex.
Aeon Biopharma held $3.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
Aeon Biopharma invested $4.1M in research and development in fiscal year 2025. This represents a decrease of 71.1% from the prior year.
Aeon Biopharma invested $4K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
AEON Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY22 | FY21 |
|---|---|---|---|---|---|
| R&D Expenses | N/A | $4.1M-71.1% | $14.2M | $34.8M | N/A |
| SG&A Expenses | N/A | $12.2M-10.5% | $13.6M | $13.7M | N/A |
| Operating Income | N/A | -$12.8M | N/A | -$48.4M-2401.6% | -$1.9M |
| Income Tax | N/A | $0 | $0 | $0 | N/A |
| Net Income | N/A | N/A | N/A | -$52.6M-740.9% | $8.2M |
| EPS (Diluted) | — | -$3.95 | $72.93 | -$0.38 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
No annual filing on record for: FY2023.
AEON Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY22 | FY21 |
|---|---|---|---|---|
| Total Assets | $5.6M+77.0% | $3.1M | $10.8M-96.1% | $276.9M |
| Current Assets | $3.4M+113.7% | $1.6M | $9.8M+1077.9% | $835K |
| Cash & Equivalents | $3.0M+23023.1% | $13K | $9.7M+1859.3% | $497K |
| Total Liabilities | $60.6M+91.1% | $31.7M | $298.3M+1.5% | $293.9M |
| Current Liabilities | $6.9M-51.3% | $14.1M | $82.6M+9794.0% | $835K |
| Total Equity | -$55.0M-92.6% | -$28.6M | -$287.5M-1598.2% | -$16.9M |
| Retained Earnings | -$470.8M-9.1% | -$431.6M | -$474.8M-2699.3% | -$17.0M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
No annual filing on record for: FY2023.
AEON Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY22 | FY21 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$13.6M | -$17.3M | N/A | -$35.6M-2280.5% | -$1.5M |
| Capital Expenditures | N/A | $4K | N/A | $306K | N/A |
| Free Cash Flow | N/A | -$17.3M | N/A | -$35.9M | N/A |
| Investing Cash Flow | N/A | -$4K | N/A | -$306K+99.9% | -$276.0M |
| Financing Cash Flow | $8.6M | $20.3M+34.1% | $15.1M | $40.5M-85.4% | $278.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
No annual filing on record for: FY2023.
AEON Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY22 | FY21 |
|---|---|---|---|---|
| Return on Assets | N/A | N/A | -487.6%-490.6pp | 3.0% |
| Current Ratio | 0.49+0.4x | 0.11 | 0.12-0.9x | 1.00 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, FCF Margin.
No annual filing on record for: FY2023.
Note: Shareholder equity is negative (-$55.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.49), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Aeon Biopharma Ranks
Frequently Asked Questions
What is Aeon Biopharma's EBITDA?
Aeon Biopharma (AEON) had EBITDA of -$12.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aeon Biopharma's free cash flow?
Aeon Biopharma (AEON) recorded an outflow of $17.3M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aeon Biopharma's operating cash flow?
Aeon Biopharma (AEON) recorded an outflow of $17.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Aeon Biopharma's total assets?
Aeon Biopharma (AEON) had $5.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Aeon Biopharma's capital expenditures?
Aeon Biopharma (AEON) invested $4K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Aeon Biopharma spend on research and development?
Aeon Biopharma (AEON) invested $4.1M in research and development during fiscal year 2025.
What is Aeon Biopharma's current ratio?
Aeon Biopharma (AEON) had a current ratio of 0.49 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Aeon Biopharma's cash runway?
Based on fiscal year 2025 data, Aeon Biopharma (AEON) had $3.0M in cash against an annual operating cash burn of $17.3M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aeon Biopharma's debt-to-equity ratio negative or not reported?
Aeon Biopharma (AEON) has negative shareholder equity of -$55.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.